NTCOC
VIRX

Northern Trust Company of Connecticut’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Northern Trust Company of Connecticut’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		$36K Hold
36
– – ﹤0.01% 1961
2013
Q3 		$38K Hold
36
– – ﹤0.01% 1934
2013
Q2 		$39K Buy
+36
New +$40.1K ﹤0.01% 1910

Other funds holding VIRX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

Northern Trust Company of Connecticut's VIRX Position: Q4 2013 in Review

Northern Trust Company of Connecticut held its Viracta Therapeutics, Inc. Common Stock (VIRX) position steady in Q4 2013 at 36 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #1961.

Northern Trust Company of Connecticut first reported a position in VIRX in Q2 2013 and has held it in 3 quarters since. The position peaked at $39K in Q2 2013. 73 funds tracked by Wall St. Rank hold VIRX as of Q4 2013.

  • Northern Trust Company of Connecticut held 36 shares of Viracta Therapeutics, Inc. Common Stock worth $36K as of Q4 2013.
  • Northern Trust Company of Connecticut left its Viracta Therapeutics, Inc. Common Stock share count unchanged in Q4 2013.
  • Viracta Therapeutics, Inc. Common Stock made up ﹤0.01% of Northern Trust Company of Connecticut's portfolio in Q4 2013, its #1961 holding.
  • Northern Trust Company of Connecticut first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 3 quarters since.
  • Northern Trust Company of Connecticut's Viracta Therapeutics, Inc. Common Stock position peaked at $39K in Q2 2013.
  • 73 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2013.

Based on Northern Trust Company of Connecticut's 13F filing for Q4 2013, filed 12 Feb 2014.